阿帕替尼联合放疗治疗非小细胞肺癌的临床研究  

Clinical observation of apatinib combined with radiotherapy in the treatment of non-small cell lung cancer

作　　者：李花妮 陈玉茹[1] 陈子彤[2] 和劲光[1] LI Huani;CHEN Yuru;CHEN Zitong;HE Jinguang(Department of Oncology,Heze Municipal Hospital,Heze 274000,Shandong,China;Department of Pharmacy,Heze Municipal Hospital,Heze 274000,Shandong,China)

机构地区：[1]菏泽市立医院肿瘤科,山东菏泽2740000 [2]菏泽市立医院药学部,山东菏泽2740000

出　　处：《癌症进展》2020年第7期699-701,724,共4页Oncology Progress

摘　　要：目的探讨阿帕替尼联合放疗治疗非小细胞肺癌(NSCLC)的临床疗效及安全性。方法依据随机数字表法将60例NSCLC患者分为观察组和对照组,每组30例,观察组患者采用阿帕替尼联合放疗,对照组患者仅采用放疗。比较两组患者的近期疗效、治疗前后的血清血管内皮生长因子(VEGF)和缺氧诱导因子-1α(HIF-1α)水平、生活质量及不良反应发生情况。结果观察组患者的总有效率为83.3%(25/30),高于对照组的56.7%(17/30),差异有统计学意义(P﹤0.05)。治疗后,两组患者的血清VEGF、HIF-1α水平均低于本组治疗前,且观察组患者的血清VEGF、HIF-1α水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者的卡氏功能状态(KPS)评分和生活质量评分均高于本组治疗前,且观察组患者的KPS评分和生活质量评分均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为33.3%(10/30),明显低于对照组的83.3%(25/30),差异有统计学意义(P﹤0.01)。结论阿帕替尼联合放疗治疗NSCLC具有协同作用,通过下调VEGF、HIF-1α的表达改善肿瘤微环境的乏氧状态,增强放疗敏感性,提高近期疗效,改善患者生活质量,且安全性较好,二者联合有望成为一种新的治疗策略。Objective To observe the clinical effect and safety of apatinib combined with radiotherapy in the treatment of non-small cell lung cancer(NSCLC).Method A total of 60 cases with NSCLC were randomized as two groups as per a random number table,with 30 cases in each,patients in the study group were treated with apatinib combined with radiotherapy,while those in the control group were given radiotherapy alone.The short-term efficacy,serum vascular endothelial growth factor(VEGF)and hypoxia-inducible factor-1α(HIF-1α)levels,quality of life(QOL),as well as the incidence of adverse reactions in the two groups were compared.Result The overall response rate in study group was 83.3%(25/30),which was significantly higher compared to the 56.7%(17/30)observed in control group(P<0.05).After treatment,the serum VEGF and HIF-1αlevels were evidently decreased in both groups,and study group demonstrated greater reduction than control group(P<0.05).The Karnofsky performance status(KPS)score and QOL score in the two groups were increased after treatment,and those in study group were significantly higher than in control group(P<0.05).The overall incidence of adverse reactions in study group was 33.3%(10/30),which was significantly lower than the 83.3%(25/30)in control group(P<0.01).Conclusion The combination of apatinib and radiotherapy exhibits synergistic effects in the treatment of NSCLC,the regimen improves the hypoxic state of tumor microenvironment,enhances the sensitivity to radiotherapy,augments the short-term efficacy,and ameliorates the QOL of patients,through down-regulation of VEGF and HIF-1αexpression,with acceptable safety,suggesting the potential to become a new treatment strategy.

关 键 词：阿帕替尼 放疗 非小细胞肺癌 总有效率 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]